A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL

Trial Details

NCT ID

NCT06855823

Phase

PHASE1 / PHASE2

Sponsor

Sun Yat-sen University

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• Golicitinib combined with Pomadomide

Locations (sample)

• Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

• Patients must demonstrate a comprehensive understanding of the study protocol, voluntarily consent to participation, and execute the informed conse…
• Inclusive of both genders, participants must be aged 18 years or older and not exceed 80 years of age.
• Histopathological confirmation of peripheral T-cell lymphoma (PTCL) must adhere to the World Health Organization (WHO) 2016 classification criteria…
• Subjects must exhibit relapsed or refractory disease following prior systemic therapy, which may include autologous hematopoietic stem cell transpl…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.